HERPUD2 (HERPUD family member 2) is predicted to participate in the unfolded protein response (UPR) pathway based on its protein binding capability and endoplasmic reticulum localization. While its direct molecular mechanism remains poorly characterized in the provided literature, HERPUD2 has emerged as a disease-relevant gene across multiple conditions. An antisense lncRNA derived from HERPUD2 (HERPUD2-AS1) is significantly upregulated in breast cancer tissues (2.13-fold increase, AUC=0.6) 1 and lung cancer, particularly non-small cell lung cancer (14.60-fold mean expression ratio) 2, where it correlates with adverse histological features including higher tumor grade and increased tubule formation. In prostate cancer, lower HERPUD2 expression associates with poor biochemical recurrence-free survival 3, suggesting a protective role. Additionally, HERPUD2 variants represent a novel susceptibility locus for early-onset hyperuricemia 4. These findings indicate HERPUD2 has dual clinical significance: its lncRNA product as a potential diagnostic biomarker for certain cancers, and its expression level as a prognostic indicator in prostate cancer. However, the mechanistic relationship between HERPUD2 protein function and these disease associations requires further investigation.